表柔比星联合多西他赛或紫杉醇治疗乳腺癌效果差异分析

目的探讨表柔比星联合多西他赛或紫杉醇治疗乳腺癌的效果差异。方法选取2018年2月至2019年7月本院收治的86例乳腺癌患者,根据动态随机分组法将其分为对照组(n=43)和观察组(n=43),对照组采用表柔比星联合紫杉醇治疗,观察组采用表柔比星联合多西他赛治疗,比较两组临床缓解率、1年内复发率、生存时间以及不良反应发生率。结果两组患者临床缓解率差异经统计学软件检验显示无统计学意义(P>0.05);观察组1年内复发率和不良反应发生率低于对照组,生存时间长于对照组,差异经统计学软件检验显示有统计学意义(P<0.05)。结论表柔比星联合多西他赛或紫杉醇对乳腺癌的治疗效果相近,但联合多西他赛的不良反应风险更低,还可延长患者生存时间。

Differential analysis of the effect of epirubicin combined with docetaxel or paclitaxel in the treatment of breast cancer

Objective:To explore the difference in the effect of epirubicin combined with docetaxel or paclitaxel in the treatment of breast cancer.Methods:A total of 86 breast cancer patients admitted to our hospital from February 2018 to July 2019 were selected and divided into a control group(n=43)and an observation group(n=43),according to the dynamic random grouping method.The control group was treated with epirubicin combined with paclitaxel,and the observation group was treated with epirubicin combined with docetaxel.The clinical remission rate,recurrence rate within one year,survival time and incidence of adverse reactions were compared between the two groups.Results:The difference in clinical remission rate between the two groups was not significant by statistical software test(P>0.05);the recurrence rate and the incidence of adverse reactions within one year in the observation group were lower than those in the control group,and the survival time was longer than that in the control group.The test showed significance(P<0.05).Conclusion:Epirubicin combined with docetaxel or paclitaxel has similar therapeutic effects on breast cancer,but combined with docetaxel has a lower risk of adverse reactions and can extend the survival time of patients,so it is recommended to promote it.